Clinical Trials Logo

Aorto-Iliac Occlusive Disease clinical trials

View clinical trials related to Aorto-Iliac Occlusive Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05805111 Not yet recruiting - Clinical trials for Aorto-iliac Occlusive Disease

Prospective, Non-Randomised Clinical Trial to Investigate the BeGraft Aortic Stent Graft System and the BeGraft Peripheral Stent Graft System Treating Aortic-iliac Occlusive Disease

Start date: July 2023
Phase:
Study type: Observational

This is a prospective, multi-center, investigational study to evaluate safety and performance of the BeGraft Aortic balloon expandable covered Stent Graft System and the BeGraft Peripheral balloon expandable covered stent Graft System (Bentley InnoMed GmbH, Hechingen, Germany) implanted as covered stents in CERAB procedures (Covered Endovascular Reconstruction of Aortic Bifurcation) for extensive aorto-iliac occlusive disease. The objective of this clinical investigation is to evaluate the safety and performance of the BeGraft Aortic covered stent Graft System & the BeGraft Peripheral covered stent Graft System (Bentley Innomed, Hechingen, Germany) in CERAB configuration (Covered Endovascular Reconstruction of Aortic Bifurcation) for Aorto-iliac Occlusive Disease.

NCT ID: NCT03824730 Completed - Clinical trials for Iliac Artery Disease

Endovascular Treatment of Aorto-iliac Occlusions

Start date: January 1, 2013
Phase:
Study type: Observational

This study compares early and long-term results of the endovascular treatment among patients with different types of aorto-iliac occlusions.

NCT ID: NCT01259908 Completed - Clinical trials for Aorto Iliac Occlusive Disease

Laparoscopic Surgical Treatment of Aorto-iliac Occlusive Disease

LAS
Start date: September 2010
Phase:
Study type: Observational

Patients with aorto-iliac occlusive disease (TASC, type D) operated with a totally laparoscopic aortobifemoral bypass operation and open aortobifemoral bypass operation will be followed up and the results will be compared between the two procedures on the basis of the primary endpoint, a composite endpoint defined as a combined incidence of systemic morbidity, graft thrombosis and all-cause mortality.